# Serotonin, Kynurenine, and Indole Pathways of Tryptophan Metabolism in Humans in Health and Disease

## TL;DR

This paper reviews how tryptophan metabolism through serotonin, kynurenine, and indole pathways is linked to various diseases and potential therapeutic strategies.

## Contribution

The paper systematically examines alterations in tryptophan catabolism pathways across multiple diseases and highlights their therapeutic potential.

## Key findings

- Tryptophan metabolism pathways are altered in diseases like depression, Alzheimer’s, and cancer.
- TRP metabolites have therapeutic potential for targeting disease mechanisms.
- Further research is needed to integrate TRP-targeted therapies into clinical strategies.

## Abstract

Tryptophan (TRP) is a proteinogenic and nutritionally essential amino acid involved in the formation of numerous bioactive substances. A crucial role in the TRP molecule is played by indole, a bicyclic ring formed by benzene and pyrrole, which confers hydrophobic and antioxidant properties and the ability to act as a ligand for aryl hydrocarbon and pregnane X receptors. The first parts of the article examine sources, nutritional requirements, and three pathways of TRP catabolism. Physiologically, ~5% of dietary TRP is catabolized through the pathway forming serotonin and melatonin in the brain and enterochromaffin cells of the gut, ~85% through the pathway resulting in the formation of nicotinamide nucleotides and kynurenine and its derivatives in the liver and immune cells, and ~10% in gut microbiota to indole derivatives. Alterations of individual TRP catabolism pathways in aging, alcoholism, inflammatory bowel disease, metabolic syndrome, renal insufficiency, liver cirrhosis, cancer, and nervous diseases, e.g., depression, Alzheimer’s and Parkinson’s diseases, multiple sclerosis, and schizophrenia, are examined in the central section. The final sections are devoted to the benefits and adverse effects of TRP supplementation, the therapeutic use of various TRP metabolites, and the pharmacological targeting of enzymes, transporters, and receptors involved in TRP catabolism. It is concluded that all pathways of TRP catabolism are altered across a broad spectrum of human illnesses, and further investigation is needed to understand their role in disease pathogenesis better. The goal for clinical research is to explore options for TRP-targeted therapies and their integration into new therapeutic strategies.